20 likes | 28 Views
Women Healthcare Market Information; by Indication (Postmenopausal Osteoporosis, Infertility, Reproductive Health Management, Polycystic Ovary Syndrome, Gynecologic Cancer and others) by diagnosis and treatment; Diagnosis (Bone Densitometry, Diagnostic Imaging Tests, Biopsies, Ovulation Testing and others), Treatment (Therapeutics, surgeries and others) by End users (Hospitals & Clinics, Gynecology Centers, Research Institutes, and others) - Global Forecast to 2023
E N D
Market Research Future Women Healthcare Market by Value, Revenue, Segments, Mega trends, Prominent Players and Outlook to 2023 Women Healthcare Market Scenario: With the growing awareness of early diagnosis, advanced treatment and growing novel drugs to treat the women health disorders among the patients and healthcare professionals has supported the growth of the market. The health of women is of particular concern as in many societies women are disadvantaged by discrimination rooted in sociocultural factors. For instance, women and girls face increased vulnerability to HIV/AIDS. Request Free Sample copy at https://www.marketresearchfuture.com/sample_request/3121 Globally, women healthcare market is dominated by several major players such as Allergan, Amgen, Bayer, BD, Eli Lily, Merck, Pfizer, Teva Pharmaceuticals and others. APAC region was the most benefited region due to the rising prevalence of the disease and rising number of treatments for women associated diseases and increasing advanced devices and therapeutics for gynecological disorders. The market for women healthcare is projected to grow at a steady CAGR of 5.04% during the forecast period from 2017-2023. Market Players of Global Women Healthcare Industry: Market players profiled in the report are Allergan plc. (Ireland), Amgen (California), Bayer A G (Germany), Becton Dickinson and Company (U.S.), Eli Lilly Company (U.S.), Merck & Co., Inc., (U.S.), Pfizer Inc., (U.S.), and Teva Pharmaceuticals (Israel). Women Healthcare Market Segments: The Women Healthcare Market is segmented on the basis of indications, diagnosis and treatment and also on the basis of end users. Based on the indications, the market has been segmented as postmenopausal osteoporosis, infertility, reproductive health management, polycystic ovary syndrome, gynecologic cancer and others. Gynecologic cancer segment has been further divided into breast, ovarian or other types of cancer. On the basis of diagnosis the market has been segmented as bone densitometry, diagnostic imaging tests, biopsies, ovulation testing and others. Similarly, on the basis of treatment the market has been classified as therapeutics, surgeries and others. Lastly on the basis of end users the market has been further classified into hospitals & clinics, gynecology centers, research institutes, and others
Market Research Future Regional Wise Analysis: On the basis of region, the market is segmented into North America, Europe, Asia-Pacific and Middle East and Africa. North America was commands the largest market share which is expected to reach USD 21,782.6 million by 2023 due to well-developed economy and initiatives taken to promote women healthcare in the region. On the other hand factors such as high cost of diagnosis and treatments are restricting the market growth in the Middle East & African region, while Asia-Pacific countries are expected to be the fastest growing region with a CAGR of 5.46% from 2017-2023. Browse Complete Report at https://www.marketresearchfuture.com/reports/women-Healthcare- market-3121 About US: Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. Contact Us: Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune - 411028 Maharashtra, India Phone: +1 646 845 9312 Email: sales@marketresearchfuture.com